Glasdegib in combination with low-dose Cytarabine for the outpatient treatment of relapsed or refractory acute myeloid leukemia in unfit patients

Andrius Zucenka¹,² · Kazimieras Maneikis² · Birute Pugaciute² · Ugne Ringeleviciute² · Austeja Dapkeviciute² · Linas Davainis² · Guoda Daukelaite¹ · Paulina Burzdikaite¹ · Vytautas Staras² · Laimonas Griskevicius¹,²

Received: 29 January 2021 / Accepted: 18 February 2021 / Published online: 4 March 2021
© The Author(s), under exclusive license to Springer-Verlag GmbH, DE part of Springer Nature 2021

Abstract
We retrospectively collected clinical data on 31 relapsed or refractory acute myeloid leukemia (R/R AML) patients who were treated with outpatient glasdegib and low-dose Cytarabine (LDAraC) at our institution. The median age was 67 years (45–86). The median Eastern Cooperative Oncology Group performance status was 2 (1–3). The patients had previously received a median number of 2 (1–4) treatment lines, 61% (19/31) had been treated with intensive chemotherapy, 29% (9/31) had relapsed after allogeneic stem cell transplantation, and 45% (14/31) had had venetoclax exposure. Adverse cytogenetics were identified in 45% (14/31) of the cases. The CR + CRp rate was 21% (6/29) among evaluable patients. The median overall survival was 3.9 months for all patients. Different median overall survival times were observed in responders, patients achieving stable disease and those diagnosed with progressive disease: not reached vs 3.9 months vs 0.8 months, respectively (p < 0.001). The most common adverse events were pneumonia (29%, 9/31), sepsis (23%, 7/31), and febrile neutropenia (16%, 5/31). Glasdegib + LDAraC is a fairly safe, non-intensive, outpatient regimen inducing complete remission and resulting in prolonged survival in some R/R AML patients.

Keywords
AML · Glasdegib · Relapsed · Refractory · Venetoclax

Introduction
The prognosis of relapsed or refractory acute myeloid leukemia (R/R AML) in elderly and unfit population remains poor as intensive salvage chemotherapy regimens cannot be administered due to excessive toxicity whereas standard low-intensity therapies often lack efficacy [1, 2]. During the last decade, a number of targeted therapies have shown promising efficacy in frontline and R/R AML settings including elderly and frail patients [3, 4]. Glasdegib is a novel small-molecule inhibitor of the Smoothened (SMO) receptor, and its efficacy is based on downregulation of the Hedgehog signaling pathway which is involved in the resistance of AML cells [5–7]. Glasdegib combined with low dose Cytarabine (LDAraC) is currently approved for newly diagnosed AML patients unfit for standard chemotherapy [8]. The pivotal phase II BRIGHT AML 1003 trial demonstrated a higher complete remission rate (17% vs 2.3%) and significantly longer median overall survival (8.8 vs 4.9 months) in unfit newly diagnosed AML patients receiving Glasdegib + LDAraC compared to the comparator arm treated with LDAraC only [9]. Cortes et al. had also presented positive efficacy, safety, and survival outcomes of AML/high-risk myelodysplastic syndrome (HR-MDS) patients treated with glasdegib in combination with standard induction 7 + 3 [10]. Glasdegib is currently being evaluated in a phase III trial in combination with either azacitidine or standard induction 7 + 3 (BRIGHT AML 1019) for previously untreated AML and several other phase I–II studies [11]. Nevertheless, glasdegib data in the R/R AML setting are lacking. We present the results of 31 heavily pretreated, elderly, and unfit R/R AML patients who were treated with glasdegib + LDAraC.

¹ Faculty of Medicine, Institute of Clinical Medicine, Vilnius University, Vilnius, Lithuania
² Bone Marrow Transplantation Department, Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santaros Klinikos, 08661 Vilnius, Lithuania

*Andrius Zucenka
andrius.zucenka@santa.lt

https://doi.org/10.1007/s00277-021-04471-6 / Published online: 4 March 2021
Methods

We retrospectively collected clinical data on R/R AML patients who were treated with glasdegib + LD AraC in 2018–2020 at Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania. Glasdegib was provided via a Compassionate Use Program by Pfizer, and the treatment was approved by the local Ethics Committee on a case by case basis. The data collection was approved by Vilnius Regional Biomedical Research Ethics Committee. All patients were at least 18 years of age, had R/R AML with no active infection or life-threatening organ toxicity, and had all treatment options exhausted.

Glasdegib + LD AraC

The treatment cycles consisted of self-administered Cytarabine 20 mg/m² s/c days 1–10 and glasdegib 100 mg p/o daily on an outpatient basis. The cycles were repeated every 28–35 days; longer interruptions were allowed in case of toxicity or social reasons. Glasdegib was continued after day 28 even if the start of the next cycle was postponed. Indications for stopping the treatment were progressive disease with no further clinical benefit observed by the treating physician, and excessive toxicity or availability of alternative treatment strategies. Routine ECG evaluation every 1–4 weeks and potassium ± magnesium supplements were administered to reduce the risk of QT prolongation in the majority of cases. Strong CYP3A4 inhibitors or drugs prolonging the QT interval were allowed if alternatives were not available; however, ECG evaluation was repeated more frequently in such cases.

Endpoints and statistical analysis

Descriptive statistics were used for baseline characteristics, safety, and efficacy analysis. For efficacy analysis, we calculated the overall response rate (ORR), which consisted of complete remission (CR), complete remission with incomplete hematological recovery (CRi), and complete remission with incomplete platelet recovery (CRp) or partial remission (PR) as defined by the European Leukemia Network 2017 (ELN 2017) criteria [12]. We calculated day 30 and day 60 mortality and recorded grade 3–5 non-hematological adverse events according to the Common Terminology Criteria of Adverse Events (CTCAE v5.0) scale. For additional toxicity evaluation, we also analyzed the prevalence of dysgeusia, anorexia, alopecia, QT prolongation, and gastrointestinal symptoms as adverse events of special interest related to glasdegib.

Fisher’s exact and Mann–Whitney U tests were used for comparison of ordinal and numerical data between the groups. Kaplan–Meier analysis was used for overall survival (OS). OS was estimated from treatment start to death from any cause with live patients censored on their last follow-up date. Reverse Kaplan–Meier analysis was used for median follow-up time evaluation. The log-rank test was used for the intergroup comparison of survival data. Univariate Cox regression analysis was used to evaluate the effect of different variables on OS. Data cutoff date was November 16, 2020. Difference with \( p < 0.05 \) was considered statistically significant.

Results

Thirty-one patients (17 female) were included in the study. Detailed baseline characteristics are summarized in Table 1. The median age was 67 years (45–86); 48% (15/31) of the patients were older than 70 years. The median Eastern Cooperative Oncology Group performance status (ECOG PS) was 2 (1–3). The patients had previously received a median number of 2 treatment lines; 29% (9/31) had been treated with 3 or 4 lines of therapy. Sixty-one percent (19/31) had previously received intensive chemotherapy regimens and 13% (4/31) had primary refractory AML. Twenty-nine percent (9/31) had relapsed after allogeneic stem cell transplantation (alloSCT). The median time from alloSCT to relapse was 89 days (51–3177) and all but one had relapsed within 12 months of alloSCT. Thirty-nine percent (12/31) had received only low-intensity therapies (hypomethylating agents (HMA)/LD AraC ± venetoclax). Of note, 45% (14/31) had previous venetoclax exposure in combination with various regimens. Adverse cytogenetics were identified in 45% (14/31) of patients, of whom 5 (16%) had complex karyotype. The most common mutations were IDH1/2 (23%, 7/31), NPM1 (16%, 5/31), ASXL1 (13%, 4/31), RUNX1 (13%, 4/31), NRAS/KRAS (10%, 3/31), FLT3-ITD/TKD (10%, 3/31), and TP53 (10%, 3/31). Based on the ELN2017 risk group stratification criteria, 16% (5/31), 26% (8/31), and 58% (18/31) of the patients were stratified into favorable, intermediate, and adverse risk groups, respectively.

Glasdegib + LD AraC treatment

A median of 2 (1–7) glasdegib + LD AraC cycles were administered. Twenty-nine percent (9/31) of the patients received at least 4 cycles. Additional hydroxyurea was used in 16% (5/31) of cases due to hyperproliferation. Treatment was stopped due to disease progression (55%, 17/31), toxicity (6%, 2/31), death in aplasia (6%, 2/31), and alloSCT (3%, 1/31). Nine patients (29%) continue glasdegib + LD AraC treatment (Fig. 1). Ninety-three percent (7/104) of all glasdegib + LD AraC cycles were administered in the outpatient setting.
Response evaluation and survival

Response was evaluated in 94% (29/31) of cases. Two patients had died during cycle 1 before response assessment. Detailed response evaluation is summarized in Table 2 and Fig. 1. CR and CRp were confirmed in 17% (5/29) and 3% (1/29) of the patients, respectively, and one patient achieved a PR. The composite CR + CRp rate was 21% (6/29), and the overall response rate (CR + CRi + CRp + PR) was 24% (7/29). The median response duration was 2 months (0.3–6). Stable disease was achieved in 48% (14/29) of patients whereas the remaining 28% (8/29) were diagnosed with progressive AML during treatment. Characteristics of responding and non-responding patients are shown in Table 3. Responders were older and less exposed to intensive chemotherapy compared to non-responders. Survival data are summarized in Figs. 2 and 3. The median overall survival was 3.9 months for all the patients. The median follow-up time was 9.4 months. Different median survival lengths were observed in responders (CR/CRp/PR), patients achieving SD, and progressive cases: not reached vs 3.9 months vs 0.8 months, respectively (p < 0.001). In a univariate Cox regression analysis (Fig. 4), older age (≥70 years) and previous non-intensive treatment only were associated with longer survival. Previous alloSCT, hyperproliferation, ECOG status, more than 1 previous treatment line, adverse cytogenetics, or previous venetoclax exposure did not have a significant impact on survival.

Toxicity

Grade 3–5 non-hematological toxicity analysis and any grade adverse events of special interest (AESI) are summarized in Table 4. The following infectious complications were the most common: pneumonia (29%, 9/31), sepsis (23%, 7/31), and febrile neutropenia (16%, 5/31). COVID-19 was diagnosed in 6% of cases (2/31) with one fatal outcome. Of note, grade 3–5 bleeding events were also relatively common: 16% (3/31) of the patients suffered from gastrointestinal bleeding, 10% (3/31) had epistaxis, and 1 patient died due to central nervous system hemorrhage. Adverse events of special interest related to glasdegib were QT prolongation (13%, 4/31), diarrhea (6%, 2/31), alopecia (6%, 2/31), gastritis (6%, 2/31), anorexia (6%, 2/31), and dysgeusia (3%, 1/31). Day 30 and day 60 all-cause mortality rates were 23% (7/31) and 29% (9/31), respectively.

Discussion

Efficacy and safety data of glasdegib + LD AraC in R/R AML setting are limited to only several reports. A case series published by Tavares et al. evaluated six elderly patients with R/R AML or HR-MDS who had previously received a median of 2 therapy lines [13]. Four patients achieved a stable disease whereas a progressive disease was diagnosed in the remaining 2 cases. No objective
responses were observed; however, 4/6 of the patients survived longer than 6 months. Salman et al. evaluated the efficacy of glasdegib monotherapy in R/R chronic myelomonocytic leukemia, myelodysplastic syndromes, or oligoblastic (20–30% blasts in the bone marrow) AML in a phase II study [14]. A total of 35 (mostly MDS, 4 with AML) patients (median age 73 years) were included. Stable disease was achieved in 56% of the patients, and 6% had hematological improvement (HI). No objective responses (CR/CRi/CRp/PR/MLFS) were observed. The median OS was 10.4 months for the whole group and 20.6 months for patients achieving SD or HI.

Our patients treated with glasdegib + LDAraC were also elderly and unfit; however, all of them had R/R AML, approximately half had secondary AML and/or adverse cytogenetics. Importantly, the majority had previously failed multiple lines of intensive chemotherapy, with some relapsing very early after alloSCT. The remaining patients were refractory to HMA or LDAraC-based therapies. Venetoclax was used in almost half of the cases as well. Unsurprisingly, the median survival of our poor prognosis group was only 3.9 months. We demonstrate a 21% composite CR + CRp rate which compares favorably to both R/R setting reports (no CR/CRi/CRp/PRs) and the pivotal phase II study in previously untreated AML/HR-MDS (17% CR rate) [9, 13, 14]. Achieving response (CR/CRp/PR) translated into a prolonged OS (all 7 responders are alive after the median follow-up time of 9.4 months, 2 are in remission (1 was bridged to alloSCT and 1 is still on Gilbertinib), and 5 relapsed). Three out of five of the relapsed patients are still receiving glasdegib + LDAraC without overt AML progression signaling the importance of continuous treatment beyond relapse. Almost half of our patients achieved AML stabilization and survived longer when compared to cases with progressive disease. Though debatable, this may suggest a
benefit of glasdegib + LDAraC in patients without objective response as already noted in the frontline and R/R glasdegib studies [13–15].

Interestingly, adverse karyotype was not associated with worse OS in our group, which differs from the data of the BRIGHT AML 1003 study [9]. Of note, previous alloSCT, hyperproliferation, number of failed treatment lines, previous venetoclax exposure or, worse ECOG PS did not impact the OS in our analysis either. On the other hand, older age and previous exposure to only low-intensity therapies (HMAs/LDAraC ± venetoclax) were associated with longer survival. Furthermore, the ORR in non-intensively pretreated patients was 55% (6/11). This may indicate the possible benefit of glasdegib + LDAraC therapy in a subgroup of elderly R/R AML patients failing HMA treatment. These patients usually face poor prognosis due to the lack of effective salvage therapies if targetable FLT3 or IDH1/2 mutations are not present [16–18]. Our previously published data and the results of this study show that glasdegib + LDAraC may have a role in AML patients failing venetoclax [19].

Table 2  Response evaluation

| Response Evaluated | n/N (%) |
|-------------------|---------|
| Response evaluated | 29/31 (94%) |
| Response not evaluated | 2/31 (6%) |

- **Best response**
  - **CR**: 5/29 (17%)
  - **CRp**: 1/29 (3%)
  - **PR**: 1/29 (3%)
  - **SD**: 14/29 (48%)
  - **PD**: 8/29 (28%)
- **CR + CRp**: 6/29 (21%)
- **CR + CRp + PR**: 7/29 (24%)

Response (CR, CRp, PR) in subgroups

- **Adverse cytogenetics**: 2/13 (15%)
- **Non-adverse cytogenetics**: 5/16 (31%)
- **Proliferative disease**: 1/9 (11%)
- **Post-alloSCT**: 0/9 (0%)
- **Previous intensive chemotherapy**: 1/18 (6%)
- **Primary refractory**: 1/4 (25%)
- **Previous low-intensity therapy only**: 6/11 (55%)
- **HMA/LDAraC ± venetoclax**
- **Previous venetoclax exposure**: 2/14 (28%)

CR: complete remission, CRp: complete remission with incomplete platelet recovery, PR: partial remission, PD: progressive disease, SD: stable disease, alloSCT: allogeneic stem cell transplantation, HMA: hypomethylating agents, LDAraC: low-dose Cytarabine

Table 3  Characteristics of responders and non-responders

|                     | Responders (7) | Non-responders (22) | p     |
|---------------------|----------------|---------------------|-------|
| Age (median, range) | 75 (67–86)     | 64 (45–84)          | 0.020 |
| Number of previous treatment lines (median, range) | 1 (1–3) | 2 (1–4) | 0.146 |
| Adverse karyotype   | 2/7 (29%)      | 11/22 (50%)         | 0.410 |
| ECOG (median, range) | 2 (1–3) | 2 (1–3) | 0.889 |
| Hyperproliferation  | 1/7 (14%)      | 8/22 (36%)          | 0.381 |
| Previous intensive chemotherapy | 1/7 (14%) | 17/22 (77%) | 0.005 |
| Post-alloSCT        | 0 (0%)         | 9/22 (41%)          | 0.066 |
| Previous venetoclax exposure | 2/7 (29%) | 12/22 (55%) | 0.389 |

Proliferative disease criteria: WBC > 10 × 10⁹/l with blasts and rapidly progressing leukocytosis and/or rapidly progressing extramedullary lesions

ECOG: Eastern Cooperative Oncology Group performance status, AlloSCT: allogeneic stem cell transplantation
Both infectious and hemorrhagic complications during glasdegib + LD AraC treatment were mainly attributable to the uncontrolled AML, and only a minority of adverse events were treatment-related. Interestingly, QT prolongation was rare, regardless of the fact that the majority of patients received multiple concomitant QT-prolonging agents (azoles, fluoroquinolones, amiodarone). Only 6% (2/31) of patients had grade 3 QT prolongation, and no episodes of life-threatening arrhythmias were observed. This may be partially explained by the prophylactic potassium and magnesium supplementation in the majority of cases and routine ECG evaluation. Other glasdegib-related toxicities (alopecia, dysgeusia, anorexia, gastrointestinal symptoms, diarrhea) were also rare. Overall, glasdegib + LD AraC was tolerated well in patients achieving response or disease stabilization and was successfully administered in the outpatient setting.

Our study has limitations. This was a retrospective, non-randomized, single-center study with a limited number of patients and a limited observation time. Nevertheless, to the best of our knowledge, this is the first report showing that glasdegib + LD AraC induces remission in poor-risk R/R AML patients with the majority achieving at least disease stabilization.

In summary, our data demonstrate that glasdegib + LD AraC is a fairly safe, non-intensive outpatient regimen that may induce complete remission and result in prolonged survival in some R/R AML patients. Older patients after low-intensity therapy failure seem to benefit the most. Larger prospective studies are warranted.
Table 4  Toxicity profile

| Adverse event                  | Total     | Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 5 |
|-------------------------------|-----------|---------|---------|---------|---------|---------|
| Non hematological CTCAE v5.0 Grade 3-5 adverse events |           |         |         |         |         |         |
| Sepsis                        | 7/31 (23%)|         |         | 1/31 (3%)| 6/31 (19%)|
| Pneumonia                     | 9/31 (29%)| 7/31 (23%)| 2/31 (6%)|         |         |
| Febrile neutropenia           | 5/31 (16%)| 5/31 (16%)|         |         |         |
| Otitis                        | 1/31 (3%) |         |         | 1/31 (3%)|         |
| Cl. Difficile enterocolitis   | 3/31 (10%)| 3/31 (10%)|         |         |         |
| Sinusitis                     | 1/31 (3%) |         |         | 1/31 (3%)|         |
| Odontogenic infection         | 3/31 (10%)| 3/31 (10%)|         |         |         |
| Mucositis                     | 4/31 (13%)| 4/31 (13%)|         |         |         |
| Skin infection                | 2/31 (6%) |         |         |         |         |
| COVID-19 infection            | 2/31 (6%) | 1/31 (3%)| 1/31 (3%)|         |         |
| Acute kidney failure          | 1/31 (3%) |         |         |         | 1/31 (3%)|
| Arthralgia/myalgia            | 3/31 (10%)| 3/31 (10%)|         |         |         |
| Fatigue                       | 1/31 (3%) |         |         | 1/31 (3%)|         |
| Delirium                      | 1/31 (3%) |         |         | 1/31 (3%)|         |
| Seizures                      | 1/31 (3%) |         |         | 1/31 (3%)|         |
| Syncope                       | 2/31 (6%) |         |         | 2/31 (6%)|         |
| Capillary leak syndrome       | 1/31 (3%) |         |         | 1/31 (3%)|         |
| Ascites                       | 1/31 (3%) |         |         | 1/31 (3%)|         |
| Hypokalemia                   | 1/31 (3%) |         |         | 1/31 (3%)|         |
| Gastrointestinal bleeding     | 2/31 (6%) |         |         | 2/31 (6%)|         |
| Epistaxis                     | 4/31 (10%)| 4/31 (13%)|         |         |         |
| CNS bleeding                  | 1/31 (3%) |         |         | 1/31 (3%)|         |
| Intraabdominal bleeding       | 1/31 (3%) |         |         | 1/31 (3%)|         |
| Oral hemorrhage               | 2/31 (6%) |         |         | 2/31 (6%)|         |
| Other hemorrhages             | 2/31 (6%) |         |         | 2/31 (6%)|         |

| Adverse events of special interest |           |         |         |         |         |         |
|-----------------------------------|-----------|---------|---------|---------|---------|---------|
| QT prolongation                   | 4/31 (13%)| 2/31 (6%)| 2/31 (6%)|         |         |
| Alopecia                          | 3/31 (10%)| 3/31 (10%)|         |         |         |
| Dysgeusia                         | 1/31 (3%) | 1/31 (3%)|         |         |         |
| Anorexia                          | 2/31 (6%) |         |         | 2/31 (6%)|         |
| Gastritis                         | 1/31 (3%) |         |         | 1/31 (3%)|         |
| Duodenal ulcer                    | 2/31 (6%) |         |         | 2/31 (6%)|         |
| Diarrhea                          | 2/31 (6%) | 2/31 (6%)|         |         |         |
| Gastric ulcer                     | 1/31 (3%) |         |         | 1/31 (3%)|         |
| Esophagitis                       | 1/31 (3%) |         |         | 1/31 (3%)|         |

CNS, central nervous system; CTCAE, Common Terminology Criteria for Adverse Events
The grey shading refers to “Not evaluated”
Code availability  (Software application or custom code): not applicable.

Author contribution  All authors had contributed to the study.

Data availability  Availability of data and material: the data that support the findings of this study are available on request from the corresponding author.

Declarations

Ethics approval and consent to participate  The study has been approved by the Vilnius Regional Biomedical Research Ethics Committee and has therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. All procedures followed were in accordance with the ethical standards of the Vilnius Regional Biomedical Research Ethics Committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008. Informed consent was obtained from all patients for being included in the study.

Consent for publication  All authors consent to the publication.

Competing interests  The authors declare no competing interests.

References

1. Ferrara F, Lessi F, Vitagliano O, Birkenghi E, Rossi G (2019) Current therapeutic results and treatment options for older patients with relapsed acute myeloid leukemia. Cancers (Basel) 11(2):224. https://doi.org/10.3390/cancers11020224
2. Bryan JC, Jabbour EJ (2015) Management of relapsed/refractory acute myeloid leukemia in the elderly: current strategies and developments. Drugs Aging 32(8):623–637
3. Daver N, Wei AH, Polleyea DA, Fathi AT, Vyas P, Dinardo CD (2020) New directions for emerging therapies in acute myeloid leukemia: the next chapter. Blood Cancer J 10(10):1–12
4. Dinardo CD, Perl AE (2019) Advances in patient care through increasingly individualized therapy. Nat Rev Clin Oncol 16(2):73–74
5. Thomas X, Heiblig M (2020) An evaluation of glasdegib for the treatment of acute myelogenous leukemia. Expert Opin Pharmacother 21(5):523–530
6. Rimkus TK, Carpenter RL, Qasem S, Chan M, Lo HW (2016) Targeting the sonic hedgehog signaling pathway: review of smoothened and GLI inhibitors. Cancers 8(2):22. https://doi.org/10.3390/cancers8020022
7. Terato T, Minami Y (2019) Targeting hedgehog (Hh) pathway for the acute myeloid leukemia treatment. Cells 8(4):312. https://doi.org/10.3390/cells8040312
8. Norsworthy KJ, By K, Subramaniam S, Zhuang L, Valle PLD, Przepiorka D et al (2019) FDA approval summary: glasdegib for newly diagnosed acute myeloid leukemia. Clin Cancer Res 25(20):6021–6025
9. Cortes JE, Heidel FH, Hellmann A, Fiedler W, Smith BD, Robak T, Montesinos P, Polleyea DA, DesJardins P, Ottmann O, Ma WW, Shaik MN, Laird AD, Zeremski M, O’Connell A, Chan G, Heuser M (2019) Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia. 33(2):379–389
10. Cortes JE, Douglas Smith B, Wang ES, Merchant A, Oehler VG, Arellano M, DeAngelo DJ, Polleyea DA, Sekeres MA, Robak T, Ma WW, Zeremski M, Naveed Shaik M, Douglas Laird A, O’Connell A, Chan G, Schroeder MA (2018) Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: phase 2 study results. Am J Hematol 93(11):1301–1310
11. Cortes JE, Dombret H, Merchant A, Tauchi T, DiRienzo CG, Sleight B et al (2019) Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials. Future Oncol 15(31):3531–3545
12. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424–447
13. Tavares M, Chacim S, Mariz JM (2020) Compassionate use of glasdegib in combination with low-dose cytarabine for relapsed, refractory acute myeloid leukemia or high-risk myelodysplastic syndrome. Ann Hematol [cited 2021 Jan 11]; Available from: https://doi.org/10.1007/s00277-020-04291-0
14. Sallman DA, Komrokji RS, Sweet KL, Mo Q, McGraw KL, Duong VH et al (2019) A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS). Leuk Res 81:56–61
15. Cortes JE, Heidel FH, Fiedler W, Smith BD, Robak T, Montesinos P, Candoni A, Leber B, Sekeres MA, Polleyea DA, Ferdinand R, Ma WW, O’Brien T, O’Connell A, Chan G, Heuser M (2020) Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy. J Hematol Oncol 13(1):92
16. Kubasch AS, Platzerbecker U (2019) The role of hypomethylating agent failure: what comes next? Haematologica. 104(8):1505–1508
17. Prébet T, Gore SD, Esterni B, Gardin C, Itzykson R, Thepot S, Dreyfus F, Rauzy OB, Recher C, Adès L, Quesnel B, Beach CL, Fenaux P, Vey N (2011) Outcome of high-risk myelodysplastic syndrome treated with glasdegib and low-dose cytarabine according to response to therapy. J Hematol Oncol 4(2):637–648
18. Komrokji RS (2015) Treatment of higher-risk myelodysplastic syndromes after failure of hypomethylating agents. Clin Lymphoma Myeloma Leuk 15:S56–S59
19. Zucenka A, Pileckyte R, Trociukas I, Peceliunas V, Vaitekenaite V, Maneikis K, et al. Outcomes of relapsed or refractory acute myeloid leukemia patients failing venetoclax-based salvage therapies. Eur J Haematol [cited 2020 Nov 2]n/a(n/a). Available from: https://doi.org/10.1111/ejh.13527

Publisher’s Note  Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.